Inhibition of antiapoptotic BCL-XL, BCL-2, and MCL-1 proteins by small molecule mimetics

Cancer Informatics

Volumn 9, Issue , 2010, Pages 169-177

  Dalafave, D S ^a   Prisco, G ^a  

^a The College of New Jersey   (United States)

Author keywords

Anticancer drug research; Apoptosis; Cancer; Small molecule mimetics

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ABT 702; ANTINEOPLASTIC AGENT; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; UNCLASSIFIED DRUG; 4 AMINO 5 (3 BROMOPHENYL) 7 (6 MORPHOLINO 3 PYRIDINYL)PYRIDO[2,3 D]PYRIMIDINE; CID 11544167; CID 11673546; CID 18177004;

ARTICLE; BINDING AFFINITY; BIOMIMETICS; COMPLEX FORMATION; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG DESIGN; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG STRUCTURE; MOLECULAR DOCKING; PROTEIN FUNCTION; APOPTOSIS; BIOINFORMATICS; DRUG EFFICACY; HUMAN; PREDICTION; PROTEIN BINDING; PROTEIN SYNTHESIS INHIBITION;

EID: 77957102794     PISSN: 11769351     EISSN: 11769351     Source Type: Journal    
DOI: 10.4137/cin.s5065     Document Type: Article

References (50)

1. Vaux DL, Cory S, Adams JM. Bcl-2 Gene Promotes Haemopoietic Cell Survival and Cooperates with C- Myc to Immortalize Pre-B Cells. Nature. 1988;335:440-2.
2. Campos L, Rouault JP, Sabido O, et al. High Expression of Bcl-2 Protein in Acute Myeloid Leukemia Cells is Associated with Poor Response to Chemotherapy. Blood. 1993;81:3091-6.
3. Waksman G, editor. Proteomics and Protein-Protein Interactions: Biology, Chemistry, Bioinformatics, and Drug Design. New York: Springer, 2005.
4. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An Inhibitor of BCL-2 Family Proteins Induces Regression of Solid Tumours. Nature. 2005;435:677-81.
5. Kann MG. Protein Interactions and Disease: Computational Approaches to Uncover the Etiology of Diseases. Brief Bioinform. 2007;8:333-46.
6. Huang DCS, Strasser A. BH3-only Proteins-Essential Initiators of Apoptotic Cell Death. Cell. 2000;103:839-42.
7. Kelekar A, Thompson CB. Bcl-2-family Proteins: The Role of the BH3 Domain in Apoptosis. Trends Cell Biol. 1998;8:324-30.
8. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 Domains Either Sensitize or Activate Mitochondrial Apoptosis, Serving as Prototype Cancer Therapeutics. Cancer Cell. 2002;2:183-92.
9. Kuwana T, Mackey MR, Perkins G, et al. Bid, Bax, and Lipids Cooperate to Form Supramolecular Openings in the Outer Mitochondrial Membrane. Cell. 2002;111:331-42.
10. Chipuk JE, Kuwana T, Bouchier-Hayes L, et al. Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis. Science. 2004;303(5660):1010-4.
11. Kim H, Rafiuddin-Shah M, Tu HC, et al. Hierarchical Regulation of Mitochondrion-Dependent Apoptosis by BCL-2 Subfamilies. Nat Cell Biol. 2006;8(12):1348-58.
12. Kuwana T, Bouchier-Hayes L, Chipuk JE, et al. BH3 Domains of BH3-only Proteins Differentially Regulate Bax-mediated Mitochondrial Membrane Permeabilization both Directly and Indirectly. Mol Cell. 2005;17:525-35.
13. Labi V, Grespi F, Baumgartner F, Villunger. A. Targeting the BCL-2-regulated Apoptosis Pathway by BH3 Mimetics: a Breakthrough in Anticancer Therapy? Cell Death Differ. 2008;15(6):977-87.
14. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 Heterodimerizes in Vivo With a Conserved Homolog, Bax, that Accelerates Programmed Cell Death. Cell. 1993;74:609-19.
15. Sharpe JC, Arnoult D, Youle RJ. Control of Mitochondrial Permeability by Bcl-2 Family Members. Biochim Biophys Acta. 2004;1644:107-13.
16. Fennell DA, Corbo MV, Dean NM, Monia BP, Cotter FE. In Vivo Suppression of Bcl-XL Expression Facilitates Chemotherapy-Induced Leukaemia Cell Death in a SCID/NOD-Hu Model. Br J Haematol. 2001;112:706-13.
17. Kaufmann SH, Karp JE, Svingen PA, et al. Elevated Expression of the Apoptotic Regulator MCL-1 at the Time of Leukemic Relapse. Blood. 1998;91:991-1000.
18. Martz L. BCL-2 Double Take. online SciBX. 2008.
19. Stauffer S. Small Molecule Inhibition of the Bcl-Xl-BH3 Protein-Protein Interaction: Proof-of-concept of an in Vivo Chemopotentiator ABT-737. Curr Top in Med Chem. 2007;7(10):961-5.
20. http://www.ncbi.nlm.nih.gov/sites/entrez?db=structure&cmd=search&term=2rod
21. Konopleva M, Contractor R, Tsao T, et al. Mechanisms of Apoptosis Sensitivity and Resistance to the BH3 Mimetic ABT-737 in Acute Myeloid Leukemia. Cancer Cell. 2006;10(5):375-88.
22. van Delft M, Weil A, Mason K, et al. The BH3 mimetic ABT-737 targets selective BCL-2 proteins and efficiently induces apoptosis via Bak/Bax if MCL-1 is neutralized. Cancer Cell. 2006;10(5):389-99.
23. Chen JH, Linstead E, Swamidass SL, Wang D, Baldi P. ChemDB Update-Full-Text Search and Virtual Chemical Space. Bioinformatics. 2007;23(17):2348-51.
24. Kang MH, Reynolds CP. Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy. Clinical Cancer Research. 2009;15:1126-32.
25. Nguyen M, Marcellus RC, Roulston A, et al. Small Molecule Obatoclax (GX15-070) Antagonizes MCL-1 and Overcomes MCL-1-mediated Resistance to Apoptosis. Proc Natl Acad Sci U S A. 2007;104:19512-7.
26. Park WH, Han YW, Kim SH, Kim SZ. An ROS Generator, Antimycin A, Inhibits the Growth of HeLa Cells via Apoptosis. J Cell Biochem. 2007;102:98-109.
27. Trudel S, Stewart AK, Li Z, et al. The BCL-2 Family Protein Inhibitor, ABT-737, Has Substantial Antimyeloma Activity and Shows Synergistic Effect with Dexamethasone and Melphalan. Clin Cancer Res. 2007;13: 621-9.
28. Lin X, Morgan-Lappe S, Huang X, et al. Seed Analysis of Off-target siRNAs Reveals an Essential Role of MCL-1 in resistance to the Small-Molecule BCL-2/Bcl-X(L) Inhibitor ABT-737. Oncogene. 2007;26:3972-9.
29. Kowaluk EA, Mikusa J, Wismer CT, et al. ABT-702 (4-Amino-5-(3-Bromophenyl)-7-(6-Morpholino-Pyridin-3-Yl)Pyrido[2,3-D]Pyrimidine), a Novel Orally Effective Adenosine Kinase Inhibitor with Analgesic and Anti-Inflammatory Properties. J Pharmacol and Exper Therap. 2000;295:3.
30. Mark A. ArgusLab 4.0.1, Thompson, Planaria Software LLC, Seattle, WA, http://www.arguslab.com/
31. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD. Improved Protein-Ligand Docking Using GOLD. Proteins. 2003;52:609-23.
32. http://autodock.scripps.edu/
33. http://zdock.bu.edu/
34. Wang G, Nikolovska-Coleska Z, Yang C-Y, et al. Structure-Based Design of Potent Small-Molecule Inhibitors of Anti-Apoptotic BCL-2 Proteins. J Med Chem Supporting Information. 2006;49(21):6139-42.
35. Wishart DS, Knox C, Guo AC, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
36. Ertl P, Rohde B, Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem. 2000;43:3714-7.
37. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. Journal of Medicinal Chemistry. 2002;45(12):2615-23.
38. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev. 1997;23:4-25.
39. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: An Environment for Comparative Protein Modeling. Electrophoresis. 1997;18:2714-23; http://www.expasy.org/spdbv/
40. http://www.organic-chemistry.org/prog/peo/
41. http://www.molinspiration.com/cgi-bin/properties
42. Day CL, Chen L, Richardson SJ, Harrison PJ, Huang DCS, Hinds MG. Solution structure of prosurvival Mcl-1 and characterization of its binding by proapoptotic BH3-only ligands. J Biol Chem. 2005;280:4738-44.
43. Lee EF, Czabotar PE, van Delft MF, et al. A novel BH3 ligand that selectively targets MCL-1 reveals that apoptosis can proceed without MCL-1 degradation. The Journal of Cell Biology. 2008;180(2):341-55.
44. Prakesch M, Denisov AY, Naim M, Gehring K, Arya P. The discovery of small molecule chemical probes of Bcl-XL and Mcl-1. Bioorganic and Medicinal Chemistry. 2008;16:7443-9.
45. High L, Szymanska B, Wilczynska-Kalak U, et al. The BH3-mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Molecular Pharmacology Fast Forward. 2009;doi:10.1124/mol.109.060780.
46. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1): 57-70.
47. Dai Y, Grant S. Targeting multiple arms of the apoptotic regulatory machinery. Cancer Res. 2007;67(7):2908-11.
48. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: A Potent and Orally Bioavailable BCL-2 Family Inhibitor. Cancer Res. 2008;68(9):3421-8.
49. Kang M, Wan Z, Kang Y, Sposto R, Reynolds C. Mechanism of Synergy of N -(4-Hydroxyphenyl) Retinamide and ABT-737 in Acute Lymphoblastic Leukemia Cell Lines: MCL-1 Inactivation. Journal of the National Cancer Institute. 2008;100(8):580-95.
50. Jarvis M, Yu H, Kohlhaas K, et al. ABT-702 (4-Amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2,3-d]pyrimidine), a Novel Orally Effective Adenosine Kinase Inhibitor with Analgesic and Anti-Inflammatory Properties: I. In Vitro Characterization and Acute Antinociceptive Effects in the Mouse. JPET. 2000;295(3):1156-64.